Teva’s Position on Access to Medicines
Teva Pharmaceutical Industries Ltd (hereinafter “Teva”), including all its directors, executives, employees and subsidiary and affiliated companies, is committed to applying our expertise and resources to advance access to quality medicine for people around the world. As the world’s leading provider of generic medicines, we are uniquely positioned to improve access to affordable treatments, including those listed on the World Health Organization’s Essential Medicines List. In line with our purpose of improving health and making people feel better, we strive to make medicines widely accessible, while continuing to deliver innovative solutions for unmet needs across our core therapeutic areas.

Generics have revolutionized the healthcare landscape, reducing costs for governments, healthcare service organizations and patients, while making quality treatment a reality for millions of individuals. Our leadership in generics is the most fundamental way in which we enhance access to medicines, and we continue to expand our generics pipeline. Yet, as even affordable medicines may not be accessible to the most disadvantaged populations, Teva adopts a strategic and comprehensive approach to enhancing access. We allocate resources to address global health priorities, as defined by United Nations Sustainable Development Goal 3: Ensure healthy lives and promote well-being for all at all ages.

Our Access to Medicines Approach and Commitments

**Increasing the reach of affordable generics:** We are committed to investing in research and development to expand our generics portfolio, as well as improving the reach of current and future generic medicines. We consider this a win-win for Teva and global health. While generics must achieve penetration across markets to justify investment in their development, they also provide access to patients and lower costs for healthcare providers. Maintaining a healthy, sustainable business affords us the opportunity to increase access. Additionally, expanding to new geographic areas increases the reach of our affordable medicines. Where possible, we also engage with governments and healthcare service organizations to establish enabling frameworks for generic medicines to reach local patients at viable costs.

**Innovating to improve access:** At Teva, one of our core competencies is the ability to create new medicines from existing ones. Use of known molecules enables quick and affordable delivery, as development requires shorter lead times and is not burdened by high costs typically associated with originator drugs. We also develop, personalize and improve treatment for disorders of the central nervous system, respiratory disease, oncology and other unmet needs. Beyond our portfolio, we help patients access physicians and other services, including support with adhering to drug regimens, and we advance access to healthcare in innovative ways, embracing technology and collaborative platforms to deliver novel, effective, scalable and affordable solutions.

**Helping to reduce healthcare costs:** We are committed to partnering to help reduce the cost of medicines for governments, payers and patients. This may include tiered or differential pricing for certain medicines or populations (provided prices are exempt from external reference pricing systems and safeguards are in place to prevent parallel trade) or collaborative programs to eliminate barriers to access (e.g., background to
help regulators and healthcare providers make informed decisions). We also seek to amplify cost savings through early adoption of generics.

**Continuously researching and innovating throughout the drug lifecycle (on or off patent):** The scale and diversity of our development and manufacturing capabilities facilitates delivery of cost-effective healthcare solutions across a wide range of therapeutic areas. To explore whether existing medicines are suitable for other patient groups, we may engage in development efforts, reformulation activities and/or introduction of delivery systems to identify additional indications. This continuous innovation process helps improve cost-efficiency by delivering additional benefits to patients, making treatments more appropriate for their needs and ecosystems.

**Partnering to advance global health:** Wherever possible, we seek partnerships to advance global health solutions and capacity building programs, particularly in emerging markets. We engage with large non-governmental organizations, foundations, healthcare institutions, technology partners and others to enhance access to medicines and mitigate known barriers.

**Supporting patients:** Our Patient Assistance Programs serve more than 300,000 patients across 45 countries. We support patient organizations, enabling members to acknowledge their right to healthcare and gain access to necessary treatments. We donate medicines to support patients with chronic illnesses, including non-communicable diseases, such as heart disease, cancer, respiratory diseases, migraine and multiple sclerosis. We also have an extensive drug donations program for emergencies and disaster relief.

**Enhancing healthcare to improve services:** We engage with healthcare organizations and industry partners to advance public policy to improve healthcare for better patient outcomes. As a member of leading industry associations, collaborative think tanks, and cross-sector forums around the world, we share our expertise and explore ways to improve healthcare.

**Governance Structure for Access to Medicines Management**

To advance Teva’s access to medicines efforts, we established a dedicated Access to Medicines Committee, reporting to our CEO and EVP, Global Brand & Communications. The Committee is chaired by the Vice President, Global Head, Environmental, Social & Governance (ESG) and staffed by other senior executives. The Committee meets twice annually and reviews Teva’s overall performance, outcomes and ongoing plans.

**Application of this Position**

This position is endorsed by Teva’s Board of Directors. We communicate this position to our employees and publicly on our website, and we share our progress in our annual ESG Progress Report.